-
Something wrong with this record ?
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
A. Sarkar, V. Novohradsky, M. Maji, T. Babu, L. Markova, H. Kostrhunova, J. Kasparkova, V. Gandin, V. Brabec, D. Gibson
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Doxorubicin pharmacology therapeutic use MeSH
- Gemcitabine MeSH
- Immunogenic Cell Death MeSH
- Humans MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neoplasms * MeSH
- Oxaliplatin pharmacology MeSH
- Prodrugs * pharmacology therapeutic use MeSH
- Antineoplastic Agents * pharmacology therapeutic use MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s ; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co-administration. The viability of CT26 cells co-cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non-treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co-administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
Czech Academy of Sciences Institute of Biophysics Kralovopolska 135 61200 Brno Czech Republic
Department of Biophysics Palacky University Slechtitelu 27 783 71 Olomouc Czech Republic
Dipartimento di Scienze del Farmaco Universita di Padova 35131 Padova Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001045
- 003
- CZ-PrNML
- 005
- 20240213093557.0
- 007
- ta
- 008
- 240109s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/anie.202310774 $2 doi
- 035 __
- $a (PubMed)37646232
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Sarkar, Amrita $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000162476272
- 245 10
- $a Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death / $c A. Sarkar, V. Novohradsky, M. Maji, T. Babu, L. Markova, H. Kostrhunova, J. Kasparkova, V. Gandin, V. Brabec, D. Gibson
- 520 9_
- $a A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s ; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co-administration. The viability of CT26 cells co-cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non-treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co-administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a oxaliplatin $x farmakologie $7 D000077150
- 650 _2
- $a gemcitabin $7 D000093542
- 650 12
- $a prekurzory léčiv $x farmakologie $x terapeutické užití $7 D011355
- 650 _2
- $a imunogenní buněčná smrt $7 D000079527
- 650 12
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
- 650 12
- $a nádory $7 D009369
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Novohradsky, Vojtech $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000343818403
- 700 1_
- $a Maji, Moumita $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000334400881
- 700 1_
- $a Babu, Tomer $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000271063629
- 700 1_
- $a Markova, Lenka $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000316406163
- 700 1_
- $a Kostrhunova, Hana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000327066491
- 700 1_
- $a Kasparkova, Jana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $u Department of Biophysics, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic $1 https://orcid.org/0000000252795381
- 700 1_
- $a Gandin, Valentina $u Dipartimento di Scienze del Farmaco, Universita di Padova, 35131, Padova, Italy $1 https://orcid.org/0000000304420670
- 700 1_
- $a Brabec, Viktor $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000282331393 $7 jo20010087133
- 700 1_
- $a Gibson, Dan $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000216314018
- 773 0_
- $w MED00000354 $t Angewandte Chemie. International edition in English $x 1521-3773 $g Roč. 62, č. 42 (2023), s. e202310774
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37646232 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093554 $b ABA008
- 999 __
- $a ok $b bmc $g 2049576 $s 1210739
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 62 $c 42 $d e202310774 $e 20230912 $i 1521-3773 $m Angewandte Chemie. International edition in English $n Angew Chem Int Ed Engl $x MED00000354
- LZP __
- $a Pubmed-20240109